3,511 results found

The Board will hold a public hearing (on a date to be determined no later than February 27, 2019) to determine whether Horizon Therapeutics Canada is selling ...

As previously reported, the Patented Medicine Prices Review Board (PMPRB) extended the consultation period for its draft Guidelines to February 14, 2020. Submissions from the consultation...

The Patented Medicine Prices Review Board (PMPRB) has released its 7th edition CompassRX report, Annual Public Drug Plan Expenditure Report for 2019/20.

On April 28, 2017, the Supreme Court of Canada dismissed Apotex's application for leave to appeal a decision of the Federal Court of Appeal

Traditionally, most Canadian cannabis companies, and more specifically, federally licensed producers looking to increase capital have looked to one place equity financing.

On February 5, 2018, Alexion Pharmaceuticals filed an application for leave to appeal a decision of the Federal Court of Appeal (FCA) ...

The September 2017 amendments to Canada's Patented Medicines Regulations introduced a new pharmaceutical patent linkage litigation scheme that more closely mirrors the US Hatch-Waxman system. This detailed comparison chart examines the similarities and differences between these two regulatory frameworks, highlighting key distinctions that remain despite the convergence.

In this peer reviewed editorial for Informa Healthcare, Carmela De Luca discusses a recent agreement between Merck and The Medicines Patent Pool to license intellectual property relating to pediatric formulations of its integrase HIV drug.

We previously reported on proposed amendments to the Patented Medicines Regulations released on December 2, 2017.

On October 26, 2017, the Federal Minister of Health tabled the 2016 Annual Report of the PMPRB with the Clerks of the House of Commons and the Senate.

On June 14, 2012, the Supreme Court of Canada ("SCC") denied leave to hear an appeal involving section 8 of the Patented Medicines (Notice of Compliance) Regulations.

Canada's whisky and spirits market presents significant opportunities for international producers, but success requires careful navigation of a dual regulatory framework. Federal laws govern production standards, excise duties, and labelling requirements, while each province maintains its own liquor authority controlling distribution, sales, marketing, and pricing within its borders. Understanding these overlapping jurisdictions and tailoring market entry strategies to provincial variations is essential for

The National Agricultural Law Group at Miller Thomson is pleased to be a partner in the preparation of the 2014 Canadian Food Industry Report.

We previously reported that the Federal Court dismissed a Patented Medicines (Notice of Compliance) (PMNOC) Regulations application relating to Apotex's generic aripiprazole product...

As previously reported here, Bill C-30 was passed by the Senate on May 11, 2017. Bill C-30 is the bill that will implement the Canada-European Union Comprehensive Economic and Trade Agreement (CETA).

The Canadian Agency for Drugs and Technologies in Health (CADTH) announced on March 8, 2018 that, effective April 2, 2018, its Common Drug Review (CDR) ...

Health Canada released a revised Guidance Document: Administrative Processing of Submissions and Applications Involving Human or Disinfectant Drugs on June 28, 2019

On July 11, 2018, the Cannabis Regulations to support the coming into force of the federal Cannabis Act were published in the Canada Gazette, Part II.